Bristol-Myers Squibb (BMY) trades 2.2% higher premarket after the company releases data today at the European Association for the Study of Liver Disease (EASL) annual meeting showing strong data on its GS-7977 Hepatitis C candidate. At a 100% cure rate for patients, the study couldn't have produced better results.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs